Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up

详细信息    查看全文

• 作者：George O Adjei (1) (4) (4)
  Jorgen AL Kurtzhals (4) (4)
  Onike P Rodrigues (1)
  Michael Alifrangis (4) (4)
  Lotte CG Hoegberg (4) (4)
  Emmanuel D Kitcher (3)
  Ebenezer V Badoe (1)
  Roberta Lamptey (2)
  Bamenla Q Goka (1)
  
• 刊名：Malaria Journal
• 出版年：2008
• 出版时间：December 2008
• 年：2008
• 卷：7
• 期：1
• 全文大小：285KB
• 参考文献：1. White NJ, Olliaro PL: Strategies for the Prevention of Antimalarial Drug Resistance: Rationale for Combination Chemotherapy for Malaria. / Parasit Today 1996, 12: 399鈥?01. CrossRef
  2. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG: Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. / PLoS Clin Trials 2006, 1: e7. CrossRef
  3. Guthmann JP, Cohuet S, Rigutto C, Fortes F, Saraiva N, Kiguli J, Kyomuhendo J, Francis M, Noel F, Mulemba M, Balkan S: High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. / Am J Trop Med Hyg 2006, 75: 143鈥?45.
  4. Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Bjorkman A: Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. / Clin Infect Dis 2005, 41: 1079鈥?086. CrossRef
  5. Taylor WR, Rigal J, Olliaro PL: Drug resistant falciparum malaria and the use of artesunate-based combinations: focus on clinical trials sponsored by TDR. / J Vector Borne Dis 2003, 40: 65鈥?2.
  6. Obonyo CO, Ochieng F, Taylor WR, Ochola SA, Mugitu K, Olliaro P, ter KF, Oloo AJ: Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial. / Trans R Soc Trop Med Hyg 2003, 97: 585鈥?91. CrossRef
  7. Niagia S: Ghana battles drug-resistant malaria with artesunate. / Lancet 2004, 363: 1372. CrossRef
  8. Organisation WH: Guidelines for the treatment of Malaria. [http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf] 2006.
  9. Oduro AR, Anyorigiya T, Koram K, Anto F, Atobrah P, Hodgson A: Amodiaquine in future combination treatment of malaria in Ghana. / Trop Doct 2007, 37: 154鈥?56. CrossRef
  10. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Bjorkman A: Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. / Infect Genet Evol 2005.
  11. Ochong EO, van B IV, Keus K, Nzila A: Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. / Am J Trop Med Hyg 2003, 69: 184鈥?87.
  12. Ehrhardt S, Eggelte TA, Kaiser S, Adjei L, Burchard GD, Anemana SD, Bienzle U, Mockenhaupt FP: Large-scale surveillance of Plasmodium falciparum crt(K76T) in northern Ghana. / Antimicrob Agents Chemother 2007, 51: 3407鈥?409. CrossRef
  13. Koram KA, Abuaku B, Duah N, Quashie N: Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. / Acta Trop 2005, 95: 194鈥?03. CrossRef
  14. Brewer TG, Peggins JO, Grate SJ, Petras JM, Levine BS, Weina PJ, Swearengen J, Heiffer MH, Schuster BG: Neurotoxicity in animals due to arteether and artemether. / Trans R Soc Trop Med Hyg 1994, 88 Suppl 1: S33-S36. CrossRef
  15. Genovese RF, Newman DB, Li Q, Peggins JO, Brewer TG: Dose-dependent brainstem neuropathology following repeated arteether administration in rats. / Brain Res Bull 1998, 45: 199鈥?02. CrossRef
  16. Elias Z, Bonnet E, Marchou B, Massip P: Neurotoxicity of artemisinin: possible counseling and treatment of side effects. / Clin Infect Dis 1999, 28: 1330鈥?331. CrossRef
  17. Franco-Paredes C, Dismukes R, Nicolls D, Kozarsky PE: Neurotoxicity due to antimalarial therapy associated with misdiagnosis of malaria. / Clin Infect Dis 2005, 40: 1710鈥?711. CrossRef
  18. Miller LG, Panosian CB: Ataxia and slurred speech after artesunate treatment for falciparum malaria. / N Engl J Med 1997, 336: 1328. CrossRef
  19. Panossian LA, Garga NI, Pelletier D: Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. / Ann Neurol 2005, 58: 812鈥?13. CrossRef
  20. Adjei GO, Goka BQ, Kurtzhals JA, Gordi T: Are currently deployed artemisinins neurotoxic? / Toxicol Lett 2006, 167: 162鈥?64. CrossRef
  21. Hatton CS, Peto TE, Bunch C, Pasvol G, Russell SJ, Singer CR, Edwards G, Winstanley P: Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. / Lancet 1986, 1: 411鈥?14. CrossRef
  22. Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J: Amodiaquine induced agranulocytosis and liver damage. / Br Med J (Clin Res Ed) 1986, 292: 721鈥?23. CrossRef
  23. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, Brasseur P: Systematic review of amodiaquine treatment in uncomplicated malaria. / Lancet 1996, 348: 1196鈥?201. CrossRef
  24. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WR: Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. / Lancet 2002, 359: 1365鈥?372. CrossRef
  25. Orrell C, Taylor WR, Olliaro P: Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. / Trans R Soc Trop Med Hyg 2001, 95: 517鈥?18. CrossRef
  26. Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F, Guthmann JP, Barnes K, Myint HY, Adjuik M, Olliaro P, Pukrittayakamee S, Looareesuwan S, Hien TT, Farrar J, Nosten F, Day NP, White NJ: In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. / Antimicrob Agents Chemother 2004, 48: 4271鈥?280. CrossRef
  27. Kofoed PE, Lopez F, Aaby P, Hedegaard K, Rombo L: Can mothers be trusted to give malaria treatment to their children at home? / Acta Trop 2003, 86: 67鈥?0. CrossRef
  28. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F, Guthmann JP: Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. / Lancet 2005, 365: 1467鈥?473. CrossRef
  29. Touwen BCL: / Examination of the child with minor neurological dysfunction London, William Heinemann Books 1979.
  30. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown KN, Viriyakosol S: Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. / Trans R Soc Trop Med Hyg 1999, 93: 369鈥?74. CrossRef
  31. Alifrangis M, Enosse S, Pearce R, Drakeley C, Roper C, Khalil IF, Nkya WM, Ronn AM, Theander TG, Bygbjerg IC: A simple high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum cloroquine resistance transporter genes using ploymerase chain reaction and enzyme linked immunosorbent assay-based technology. / Am J Trop Med Hyg 2005, 72: 155鈥?62.
  32. World Health Organisation: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. 2003.
  33. Edwards IR, Aronson JK: Adverse drug reactions: definitions, diagnosis, and management. / Lancet 2000, 356: 1255鈥?259. CrossRef
  34. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ: Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. / Lancet 2005, 365: 1474鈥?480. CrossRef
  35. Guthmann JP, Pinoges L, Checchi F, Cousens S, Balkan S, van HM, Legros D, Olliaro P: Methodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004. / Antimicrob Agents Chemother 2006, 50: 3734鈥?739. CrossRef
  36. Hamour S, Melaku Y, Keus K, Wambugu J, Atkin S, Montgomery J, Ford N, Hook C, Checchi F: Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations. / Trans R Soc Trop Med Hyg 2005, 99: 548鈥?54. CrossRef
  37. Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ: Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. / Antimicrob Agents Chemother 2007, 51: 3023鈥?025. CrossRef
  38. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN: Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. / Lancet 2007, 369: 757鈥?65. CrossRef
  39. Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde RT, Rosenthal PJ, Ouedraogo JB: Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. / Lancet 2007, 369: 491鈥?98. CrossRef
  40. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, Ouedraogo JB: Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. / Clin Infect Dis 2007, 45: 1453鈥?461. CrossRef
  41. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI: Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. / Trans R Soc Trop Med Hyg 2005, 99: 459鈥?67. CrossRef
  42. Gasasira AF, Dorsey G, Nzarubara B, Staedke SG, Nassali A, Rosenthal PJ, Kamya MR: Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. / Am J Trop Med Hyg 2003, 68: 127鈥?32.
  43. Dale DC, Wolff SM: Studies of the neutropenia of acute malaria. / Blood 1973, 41: 197鈥?06.
  44. Sheagren JN, Tobie JE, Fox LM, Wolff SM: Reticuloendothelial system phagocytic function in naturally acquired human malaria. / J Lab Clin Med 1970, 75: 481鈥?87.
  45. Lind DE, Levi JA, Vincent PC: Amodiaquine-induced agranulocytosis: toxic effect of amodiaquine in bone marrow cultures in vitro. / Br Med J 1973, 1: 458鈥?60. CrossRef
  46. Rhodes EG, Ball J, Franklin IM: Amodiaquine induced agranulocytosis: inhibition of colony growth in bone marrow by antimalarial agents. / Br Med J (Clin Res Ed) 1986, 292: 717鈥?18. CrossRef
  47. Clarke JB, Maggs JL, Kitteringham NR, Park BK: Immunogenicity of amodiaquine in the rat. / Int Arch Allergy Appl Immunol 1990, 91: 335鈥?42. CrossRef
  48. Clarke JB, Neftel K, Kitteringham NR, Park BK: Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. / Int Arch Allergy Appl Immunol 1991, 95: 369鈥?75. CrossRef
  49. Price R, van VM, Phaipun L, Luxemburger C, Simpson J, McGready R, ter KF, Kham A, Chongsuphajaisiddhi T, White NJ, Nosten F: Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. / Am J Trop Med Hyg 1999, 60: 547鈥?55.
  50. Petras JM, Kyle DE, Gettayacamin M, Young GD, Bauman RA, Webster HK, Corcoran KD, Peggins JO, Vane MA, Brewer TG: Arteether: risks of two-week administration in Macaca mulatta. / Am J Trop Med Hyg 1997, 56: 390鈥?96.
  51. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PM, Laihad F, Anstey NM, Tjitra E, Price RN: Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. / Clin Infect Dis 2007, 44: 1067鈥?074. CrossRef
  
• 作者单位：George O Adjei (1) (4) (4)
  Jorgen AL Kurtzhals (4) (4)
  Onike P Rodrigues (1)
  Michael Alifrangis (4) (4)
  Lotte CG Hoegberg (4) (4)
  Emmanuel D Kitcher (3)
  Ebenezer V Badoe (1)
  Roberta Lamptey (2)
  Bamenla Q Goka (1)
  
  1. Department of Child Health, Korle Bu Teaching Hospital, University of Ghana Medical School, P. O. Box KB 4236, Accra, Ghana
  4. Centre for Medical Parasitology at Department of Clinical Microbiology and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Denmark
  4. Department of International Health, Immunology and Microbiology, University of Copenhagen, Denmark
  3. Ear, Nose and Throat Unit, Korle Bu Teaching Hospital, Accra, Ghana
  2. Polyclinic, Korle Bu Teaching Hospital, Accra, Ghana
  

文摘

Background Artesunate-amodiaquine (AS+AQ) and artemether-lumefantrine (AM-L) are efficacious artemisinin combination therapy (ACT) regimens that have been widely adopted in sub-Saharan Africa. However, there is little information on the efficacy of these regimens on subsequent episodes beyond 28 days, or on the safety of repeated treatments. Methods Children aged six months to 14 years with uncomplicated malaria were randomly assigned to treatment with AS+AQ (n = 116), or AM-L (n = 111). Recruited subjects were followed-up, initially for 28 days, and then monthly for up to one year. All subsequent attacks of uncomplicated malaria after 28 days were treated with the same regimen as at randomization. Investigations aimed at determining efficacy and side effects were conducted. Results Adequate clinical and parasitological response in subjects with evaluable end-points were, 97.1% (100/103) and 98.2% (107/109) on day 14, and 94.2% (97/103) and 95.3% (102/107) on day 28 in the AM-L and AS+AQ groups, respectively. Similar results were obtained after PCR correction. The incidence of malaria attacks in the year following recruitment was similar between the two treatment groups (p = 0.93). There was a high incidence of potentially AQ-resistant parasites in the study area. The incidence of adverse events, such as pruritus, fatigue and neutropaenia were similar in the two treatment groups. No patient showed signs of hearing impairment, and no abnormal neurological signs were observed during one year of follow-up. Other adverse events were mild in intensity and overlapped with known malaria symptomatology. No adverse event exacerbation was observed in any of the subjects who received multiple treatment courses with these ACT regimens during one year follow-up. Conclusion AS+AQ and AM-L were efficacious for treatment of children with uncomplicated malaria in Ghana and drug-related adverse events were rare in treated subjects during one year of follow-up. The high prevalence of potentially AQ resistant parasites raises questions about the utility of AQ as a partner drug for ACT in Ghana. The efficacy of AS+AQ in Ghana requires, therefore, continuous monitoring and evaluation. Trial registration NCT 00406146 http://www.clinicaltrials.gov